Home Companies TELA Bio COMPANY
FDA-cleared device company
1 open job · last seen Oct 23, 2026 · 8 sources
Location: Malvern, PA · source · Oct 13, 2026
Profile checked Oct 10, 2026
Keywords: Ventral Hernia Breast Reconstruction Reconstructive Surgical Procedures Hiatal Hernia Inguinal Hernia OviTex Reinforced Tissue Matrix OviTex PRS OviTex® PRS OviTex 1S Permanent Show all 9 keywords
At a glance HQ Malvern, PA source Stage FDA-cleared device company Latest trial Not phased (device or behavioral study): Effectiveness and Safety of OviTex® PRS in Breast Reconstruction (Apr 10, 2026) source Timeline Apr 10, 2026 Trial start Not phased (device or behavioral study): Effectiveness and Safety of OviTex® PRS in Breast Reconstruction source ↗ Nov 13, 2025 Raise Follow-on offering — Registered direct: $13M (total, as published), announced Nov 13, 2025. Source: company release on GlobeNewswire. source ↗ Nov 13, 2025 Debt Debt: $20.7M (not counted as a raise), announced Nov 13, 2025. Source: company release on GlobeNewswire. source ↗ Jul 25, 2025 Trial start Not phased (device or behavioral study): Evaluating Clinical Hiatal Hernia Outcomes Using OviTex® source ↗ Oct 24, 2024 Raise Follow-on offering: $46M (total, as published), announced Oct 24, 2024. Source: company release on GlobeNewswire. source ↗ Sep 27, 2022 Trial start —: A Retrospective Assessment of OviTex PRS (OviTex) source ↗ Apr 29, 2021 Trial start Not phased (device or behavioral study): Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh source ↗ Apr 24, 2017 Trial start Not phased (device or behavioral study): Ventral Hernia Study Using OviTex Reinforced Bioscaffold source ↗ Upcoming milestones Mar 30, 2027 (ESTIMATED) · Not phased · Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh · NCT04779918 2030-06 (ESTIMATED) · Not phased · Effectiveness and Safety of OviTex® PRS in Breast Reconstruction · NCT07135596 Dec 31, 2031 (ESTIMATED) · Not phased · Evaluating Clinical Hiatal Hernia Outcomes Using OviTex® · NCT07070115 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $59.0M · Debt: $20.7M. Last 2 years.
Nov 13, 2025 Follow-on offering — Registered direct: $13M (total, as published), announced Nov 13, 2025. Source: company release on GlobeNewswire. source ↗ Oct 24, 2024 Follow-on offering: $46M (total, as published), announced Oct 24, 2024. Source: company release on GlobeNewswire. source ↗ Nov 13, 2025 Debt: $20.7M (not counted as a raise), announced Nov 13, 2025. Source: company release on GlobeNewswire. source ↗ Clinical trials (lead sponsor) 5 Record Title Phase Status Start Primary completion NCT07135596 Effectiveness and Safety of OviTex® PRS in Breast Reconstruction Not phased (device or behavioral study) Recruiting Apr 10, 2026 2030-06 (estimated) NCT05736848 A Retrospective Assessment of OviTex PRS (OviTex) Not listed Active, not recruiting Sep 27, 2022 Aug 30, 2026 (estimated) NCT07070115 Evaluating Clinical Hiatal Hernia Outcomes Using OviTex® Not phased (device or behavioral study) Recruiting Jul 25, 2025 Dec 31, 2031 (estimated) NCT04779918 Ventral or Inguinal Hernia, Robotically Repaired With OviTex Mesh Not phased (device or behavioral study) Recruiting Apr 29, 2021 Mar 30, 2027 (estimated) NCT03074474 Ventral Hernia Study Using OviTex Reinforced Bioscaffold Not phased (device or behavioral study) Completed Apr 24, 2017 Dec 8, 2019 (actual)
Raises and investors new Form D raises come from the company’s own SEC filing (last 2 years).
Investor Listed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗ Open jobs 1 Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
